Neuromyelitis Optica Spectrum Disorder (NMOSD)
Neuromyelitis optica spectrum disorder is an autoimmune astrocytopathy, most often mediated by antibodies against aquaporin-4, that predominantly causes severe optic neuritis and longitudinally extensive transverse myelitis.
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Neuromyelitis optica spectrum disorder (NMOSD), historically known as Devic's disease, is a severe, relapsing, autoimmune, inflammatory disorder of the central nervous system (CNS) characterised by immune-mediated demyelination and axonal damage predominantly targeting optic nerves and spinal cord [1][2].
Breaking down the name from its roots:
- "Neuro" = nerve (Greek neuron)
- "Myel" = spinal cord (Greek myelos)
- "Itis" = inflammation
- "Optica" = relating to the eye / optic nerve
- "Spectrum" = reflecting that the condition encompasses a range of clinical presentations beyond the classic optic neuritis + myelitis pair
So the name literally tells you: inflammation of the nerves, spinal cord, and optic pathways — across a spectrum of severity.
The disease is fundamentally an autoimmune astrocytopathy [3] — meaning it is a disease of astrocytes, not primarily of myelin (unlike MS). The hallmark autoantibody is anti-aquaporin-4 (AQP4-IgG), which targets the AQP4 water channel located on the foot processes of astrocytes [2][4]. This is what biologically and clinically separates NMOSD from multiple sclerosis (MS).
"Detection of disease-specific anti-aquaporin-4 (AQP4) antibody is specific for NMO and is what separates it from the clinical entity of MS" [1]
Key Conceptual Point
NMOSD is an astrocytopathy (disease of astrocytes), not a primary demyelinating disease. Demyelination occurs secondarily to astrocyte destruction. This is fundamentally different from MS, which is a primary demyelinating disease of oligodendrocytes. Understanding this distinction is critical for both pathophysiology and treatment decisions.
2. Epidemiology
- Prevalence: approximately 0.5–4 per 100,000 worldwide; varies significantly by ethnicity and geography
- More common in Asians compared to Caucasians [2] — this is the opposite of MS, which predominantly affects Caucasians
- In Hong Kong and East Asia, NMOSD constitutes a proportionally larger fraction of CNS inflammatory demyelinating diseases compared to Western populations
- Among patients previously diagnosed with "MS" in Asia, a significant proportion were reclassified as NMOSD after AQP4-IgG testing became available
| Feature | NMOSD | MS (for comparison) |
|---|---|---|
| Age of onset | Late 30s – 50 | 20–40 |
| M:F ratio | 1:9 | 1:2 |
| Racial predilection | Asians | Caucasians |
- The striking female predominance (1:9) in NMOSD is even more dramatic than MS (1:2), suggesting a strong hormonal or X-linked genetic component
- Can occur in children and elderly, though peak onset is in the 4th–5th decade
- ≥90% have a relapsing course [5] — monophasic disease is rare (< 10%)
- Often more severe and disabling vs. multiple sclerosis [4]
- Attacks often more severe with 25–50% mortality and significant residual deficits [5]
- Stepwise deterioration with each relapse [5] — unlike MS which has a more gradual progressive phase
3. Risk Factors
- Female sex: 90% of patients are female
- Asian, African, or Hispanic ethnicity: higher prevalence relative to Caucasians
- Age: peak onset 30s–50s
- Genetic susceptibility: HLA associations differ from MS (HLA-DRB1*03 linked to AQP4-IgG+ NMOSD in some populations)
- Other autoimmune diseases: NMOSD frequently co-occurs with:
- Systemic lupus erythematosus (SLE)
- Sjögren's syndrome
- Myasthenia gravis
- Autoimmune thyroid disease
- This autoimmune clustering supports the idea that NMOSD patients have a generalised tendency toward autoimmunity
- Preceding infections: may trigger relapses through molecular mimicry or non-specific immune activation
High Yield – Asian Female with Bilateral Optic Neuritis
In HKUMed exams, always think NMOSD in an Asian middle-aged female presenting with bilateral optic neuritis and/or longitudinally extensive transverse myelitis (LETM). Do NOT assume MS — the epidemiology strongly favours NMOSD in this demographic.
4. Anatomy and Function
AQP4 is a water channel protein located at the foot processes of astrocytes [2][3]. Understanding where AQP4 is concentrated explains why certain areas of the CNS are preferentially attacked:
| AQP4-Rich Region | Corresponding Clinical Syndrome |
|---|---|
| Optic nerves | Optic neuritis |
| Spinal cord (central grey matter) | Longitudinally extensive transverse myelitis |
| Area postrema (floor of 4th ventricle) | Intractable hiccups, nausea/vomiting |
| Hypothalamus | Endocrine dysfunction, narcolepsy |
| Periependymal regions (around ventricles) | Periventricular brain lesions |
| Cerebral cortex (lower density) | Encephalopathy (less common) |
Why the area postrema? The area postrema is one of the circumventricular organs — it lies outside the blood-brain barrier (BBB), meaning circulating AQP4-IgG antibodies can access it directly without needing BBB breakdown. This explains why area postrema syndrome can be an early or presenting feature of NMOSD.
Astrocytes form the glia limitans — a cellular layer wrapping around blood vessels in the CNS, forming part of the BBB. Their foot processes express AQP4, which:
- Regulates water homeostasis in the CNS
- Maintains ion balance around neurons
- Supports the BBB integrity
When AQP4-IgG binds to these foot processes → complement-mediated astrocyte destruction → BBB breakdown → secondary inflammation → secondary demyelination and axonal damage
Why is NMOSD worse than MS?
In MS, primary demyelination can be repaired by remyelination (oligodendrocyte precursors). In NMOSD, the primary target is the astrocyte — once the astrocyte is destroyed, both the myelin AND the axon are damaged secondarily, leading to more severe, irreversible deficits with each attack. This is why NMOSD has "demyelination + axonal degeneration" (cf. MS) [2].
5. Etiology and Pathophysiology
NMOSD is a B-cell mediated, complement-dependent autoimmune disease:
- B cells produce AQP4-IgG (predominantly IgG1 subclass — the most potent complement-fixing IgG subclass)
- AQP4-IgG crosses into the CNS (via areas without BBB or during BBB disruption)
- Binds to AQP4 on astrocyte foot processes
- Activates classical complement pathway (C1q → C4b2a → C3 convertase → C5b-9 membrane attack complex)
- Complement-mediated astrocyte lysis (astrocytopathy)
- Loss of astrocytic support → secondary oligodendrocyte death → demyelination
- Loss of trophic support → axonal degeneration
- Inflammatory infiltrate: characteristically includes neutrophils, eosinophils, and macrophages (unlike MS which is T-cell/lymphocyte dominant)
The pathology of an NMOSD lesion is therefore: astrocyte loss → demyelination → axonal loss → necrosis (in severe cases, can see cavitation/necrosis — rarely seen in MS)
- Anti-AQP4 / NMO-IgG is present in ~60-80% of NMOSD patients [2]
- 100% specific, ~72% sensitive [5]
- IgG1 subclass → potent complement activator
- Titre may correlate with disease activity
- Seronegative NMOSD exists (~20-30%):
- Some have MOG-IgG (myelin oligodendrocyte glycoprotein antibodies) → now classified as a separate entity: MOGAD (MOG antibody-associated disease)
- Some are truly seronegative (diagnosis based on clinical + MRI criteria)
| Feature | NMOSD | MS |
|---|---|---|
| Primary target | Astrocyte (AQP4) | Oligodendrocyte / Myelin |
| Primary mechanism | Humoral (B-cell, complement) | Cellular (T-cell) + humoral |
| Inflammatory infiltrate | Neutrophils, eosinophils | Lymphocytes (T cells) |
| Pathology | Astrocyte loss → secondary demyelination → necrosis | Primary demyelination, relative axonal sparing |
| Severity per attack | Severe, poor recovery | Usually milder, good early recovery |
| Oligoclonal bands | Usually absent | Present in ~90% |
MOG-IgG (myelin oligodendrocyte glycoprotein antibodies) define a distinct entity now separated from NMOSD [6]:
- MOG is expressed on the outermost surface of the myelin sheath (oligodendrocyte)
- MOGAD can present as optic neuritis, myelitis, or ADEM (especially in children)
- Different prognosis and treatment considerations from AQP4-IgG+ NMOSD
- Generally better recovery than AQP4+ NMOSD
CNS inflammatory demyelinating diseases (IDD) include: MS, NMOSD, and MOG-IgG+ disease (ADEM, ON, myelitis, etc.) [2]
6. Classification
| Category | Description |
|---|---|
| AQP4-IgG seropositive NMOSD | ~70-80%; definite NMOSD with anti-AQP4 antibodies; requires only 1 core clinical characteristic |
| AQP4-IgG seronegative NMOSD | ~20-30%; requires at least 2 core clinical characteristics + additional MRI criteria |
| MOG-IgG positive | Now reclassified as MOGAD — separate entity from NMOSD |
| Double seronegative | No AQP4-IgG, no MOG-IgG; diagnosis by clinical + imaging criteria; rare |
| Pattern | Frequency | Description |
|---|---|---|
| Relapsing | > 90% | Recurrent attacks with incomplete recovery; this is the dominant pattern |
| Monophasic | < 10% | Single attack without recurrence; more common in MOG-IgG+ patients |
The six core clinical characteristics of NMOSD are [6][7]:
- Optic neuritis
- Acute myelitis
- Area postrema syndrome (intractable hiccups/nausea/vomiting)
- Acute brainstem syndrome
- Symptomatic narcolepsy or acute diencephalic syndrome (with diencephalic MRI lesions)
- Symptomatic cerebral syndrome (with typical brain lesions)
7. Clinical Features
- Relapsing course [4]
- Often more severe and disabling vs. multiple sclerosis [4]
- Cardinal features: optic neuritis, acute myelitis, brainstem syndromes [4]
- Less recovery, more relapses (> 90%) [2]
- Each attack tends to leave significant residual disability — unlike early MS where recovery between relapses is often good
7.2 Symptoms
- Acute-subacute visual loss (often severe and binocular) [4]
- Pain on eye movement (due to traction on the inflamed optic nerve sheath by the rectus muscles during eye movement)
- Colour desaturation [4] — loss of colour vision, often disproportionate to the degree of visual acuity loss
Pathophysiological basis: AQP4 is highly expressed on astrocytes surrounding the optic nerve → AQP4-IgG binding → complement-mediated astrocyte destruction → secondary demyelination and axonal damage of optic nerve fibres → loss of visual signal transmission
Key distinguishing features from MS-related optic neuritis:
| Feature | NMOSD Optic Neuritis | MS Optic Neuritis |
|---|---|---|
| Laterality | Usually bilateral (simultaneous or rapidly sequential) [2] | Usually unilateral |
| Severity | More severe visual loss [5][8] | Milder, usually recovers well |
| Recovery | Poor; significant residual visual deficit | Usually good recovery |
| Optic nerve lesion on MRI | Longer lesions (often > 1/2 optic nerve length), may extend to chiasm | Shorter lesions |
"NMO-related ON are indistinguishable from MS-related ON but visual loss is generally more severe and may have sequential ON in rapid succession or bilateral simultaneous optic neuritis in NMO (cf. usually unilateral in MS)" [8]
- Often with longitudinally extensive transverse myelitis (LETM) spanning at least 3 spinal segments [4]
- Develops over hours to days
- Motor symptoms: symmetrical paraparesis/quadriparesis [5], tends to be more complete than MS
- Why symmetrical? Because the lesion involves the central grey matter of the spinal cord (where AQP4 is concentrated), affecting bilateral corticospinal tracts
- Sensory symptoms: numbness and paraesthesia, sensory loss with a clear sensory level [5]
- A "sensory level" means loss of sensation below a specific dermatome — this localises the lesion to the spinal cord
- Autonomic symptoms: bladder dysfunction [5] (urinary retention, incontinence), bowel dysfunction, sexual dysfunction
- Because the central cord lesion affects the autonomic pathways running in the intermediolateral cell column and the sacral parasympathetic nuclei
- Respiratory failure can occur with cervical cord involvement [5] (C3-5 phrenic nerve) — this is a neurological emergency
Pathophysiological basis: AQP4 is concentrated in the central grey matter of the spinal cord (around the central canal, where astrocytes are dense) → AQP4-IgG mediated astrocyte destruction → extensive necrotic lesion spanning ≥3 vertebral segments → bilateral corticospinal, spinothalamic, dorsal column, and autonomic pathway damage
Why LETM and not short segments?
- In MS, lesions are caused by focal perivascular inflammation → small, scattered plaques → short segment myelitis (usually < 2 segments)
- In NMOSD, the primary target (AQP4 on astrocytes) is distributed along the central canal of the spinal cord continuously → complement-mediated damage spreads along this continuous distribution → longitudinally extensive lesion
Presentation: intractable hiccups, nausea/vomiting [2]
- Can be the initial or only presentation of NMOSD
- Often misdiagnosed as a GI problem before neurological features emerge
Pathophysiological basis: The area postrema is located at the floor of the fourth ventricle. It is a circumventricular organ — meaning it lies outside the blood-brain barrier. AQP4 is highly expressed here. Because there is no BBB, circulating AQP4-IgG antibodies can freely access and attack astrocytes in this region, even before BBB is disrupted elsewhere. The area postrema is the brain's "vomiting centre" / chemoreceptor trigger zone → its destruction causes intractable nausea, vomiting, and hiccups.
"Lower brainstem: area postrema syndrome (intractable hiccups, n/v)" [2]
Clinical Pearl – Area Postrema Syndrome
If a patient presents with intractable hiccups and vomiting that don't respond to antiemetics, with a negative GI workup — think NMOSD! This can precede optic neuritis or myelitis by weeks to months. Order AQP4-IgG and MRI brain focusing on the dorsal medulla.
- Various brainstem manifestations depending on lesion location
- No INO (internuclear ophthalmoplegia) — this is a distinguishing feature from MS [2]
- Why? In MS, small periventricular plaques commonly affect the MLF (medial longitudinal fasciculus) in the pons → INO. In NMOSD, brainstem lesions tend to affect the dorsal medulla/area postrema region and periependymal areas, sparing the MLF
- Other brainstem symptoms: diplopia, facial numbness, vertigo, hearing loss
- Hypothalamic involvement: can cause
- Symptomatic narcolepsy (hypocretin/orexin neuron damage)
- Hypothermia
- SIADH
- Endocrine dysfunction
- Less common but recognised in the 2015 criteria
- Large, tumefactive, or confluent white matter lesions
- Can mimic ADEM or tumour
- Less common; when present, tends to involve periependymal regions (reflecting AQP4 distribution around ventricles)
7.3 Signs
- Relative afferent pupillary defect (RAPD): ALWAYS present if the other eye is uninvolved [4] — the swinging flashlight test shows paradoxical pupil dilation when light is shone in the affected eye because the afferent limb (optic nerve) is damaged
- Decreased visual acuity — often severe (can be < 6/60 or even no light perception)
- Optic disc oedema [4] — swollen, hyperaemic disc on fundoscopy (in papillitis / anterior optic neuritis)
- Visual field defect: central or centrocaecal scotoma
- Colour desaturation: tested with Ishihara plates; disproportionate to VA loss
- Optic atrophy: in chronic/recurrent cases, temporal pallor of the optic disc
- Spastic paraparesis or quadriparesis: increased tone, hyperreflexia, upgoing plantars (Babinski sign positive)
- Why UMN signs? Because the lesion is in the spinal cord (upper motor neuron) → loss of descending inhibition on spinal reflexes
- Sensory level: a clear dermatomal level below which sensation (pain, temperature, light touch) is diminished or absent
- Bladder distension: palpable on examination in urinary retention
- In acute phase: may initially show spinal shock with flaccid paralysis and areflexia before UMN signs develop (takes days to weeks)
- Clinical signs are primarily the symptoms themselves (intractable hiccups, vomiting)
- No specific examination signs, but the clinical context + MRI is diagnostic
| Sign | NMOSD | MS |
|---|---|---|
| INO (internuclear ophthalmoplegia) | No INO [2] | Common (bilateral INO classic) |
| Lhermitte's sign | May be present | Classic for MS |
| Uhthoff's phenomenon | Less characteristic | Classic for MS |
| Cerebellar signs | Uncommon | Common |
This table is extremely high-yield for exams [2][4][5]:
| Feature | MS | NMOSD |
|---|---|---|
| Age of onset | 20–40 | Late 30s – 50 |
| M:F | 1:2 | 1:9 |
| Race | Caucasians | Asians |
| Primary target | Oligodendrocyte/myelin | Astrocyte (AQP4) |
| Optic neuritis | Unilateral | Usually bilateral |
| Brainstem | INO, gaze palsies | Area postrema syndrome (intractable hiccups, n/v), no INO |
| Spinal cord | Short segment (< 2 segments) | LETM (≥3 consecutive spinal segments) — symmetrical paraparesis, sensory level, autonomic failure |
| Disease course | 85% RRMS, can become SPMS | > 90% relapsing, stepwise deterioration |
| Serology | Negative | Anti-AQP4 / NMO-IgG (60-80%) |
| CSF | WBC < 25, Oligoclonal bands (90%) | Pleocytosis (↑WBC), No oligoclonal bands |
| MRI brain | Demyelinating hyperintense lesions (periventricular, Dawson's fingers) | Atypical changes (50%), brainstem lesions (15%) |
| MRI spine | Shorter segments | ≥3 consecutive spinal segments (LETM) |
| Acute treatment | Steroids, plasma exchange | Steroids, plasma exchange, IVIG |
| Long-term DMT | IFNβ, teriflunomide, fingolimod, natalizumab | Immunosuppressants (azathioprine, MMF, rituximab) |
CRITICAL Exam Point — Do NOT Use MS Drugs for NMOSD
Disease-modifying drugs for MS (beta-IFN, DMF, fingolimod, natalizumab, alemtuzumab) should NOT be used in NMOSD: ineffective/worsen disease [6]. This is one of the most commonly tested points. MS drugs like fingolimod and natalizumab can actually exacerbate NMOSD attacks. Always test for AQP4-IgG before starting MS-specific DMTs in any patient with CNS demyelinating disease, especially in Asian populations.
Key abbreviations [6]:
| Abbreviation | Full Form |
|---|---|
| ADEM | Acute disseminated encephalomyelitis |
| AQP4 | Aquaporin 4 |
| AQP4-IgG | AQP4 antibodies, IgG1 subclass |
| GFAP | Glial fibrillary acidic protein |
| LETM | Longitudinally extensive transverse myelitis |
| MOG | Myelin oligodendrocyte glycoprotein |
| MOG-IgG | MOG antibodies, IgG1 subclass |
| MOGAD | MOG antibody-associated disease |
| NfL | Neurofilament light chain |
| NMOSD | Neuromyelitis optica spectrum disorder |
| OCBs | Oligoclonal bands |
High Yield Summary
Definition: NMOSD is an autoimmune astrocytopathy caused by AQP4-IgG targeting water channels on astrocyte foot processes → complement-mediated astrocyte destruction → secondary demyelination and axonal degeneration.
Epidemiology: Asian females (M:F 1:9), onset 30s–50s. More common in Asians (cf. MS in Caucasians).
Cardinal features (3):
- Optic neuritis — bilateral, severe, poor recovery
- LETM — ≥3 spinal segments, symmetrical paraparesis, sensory level, autonomic failure
- Area postrema syndrome — intractable hiccups, nausea/vomiting (unique to NMOSD)
Key lab findings: AQP4-IgG positive (60-80%), CSF pleocytosis WITHOUT oligoclonal bands
Critical management point: MS-specific DMTs (IFNβ, fingolimod, natalizumab, DMF, alemtuzumab) are CONTRAINDICATED — they worsen NMOSD. Use immunosuppressants: azathioprine, MMF, rituximab.
Prognosis: > 90% relapsing course, stepwise deterioration, 25-50% mortality, significant residual deficits per attack.
Key differences from MS: bilateral ON (not unilateral), LETM (not short segment), no oligoclonal bands (not present 90%), no INO, Asian > Caucasian, astrocytopathy (not primary demyelination).
Active Recall - NMOSD Overview, Epidemiology, Pathophysiology and Clinical Features
[1] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf – Section on Neuromyelitis optica (NMO) [2] Senior notes: Maksim Medicine Notes.pdf – Section 11.8 CNS demyelinating diseases, MS vs NMOSD table [3] Senior notes: learning_points_output.txt – Neurology: Two Cases of Lower Limb Weakness learning points [4] Lecture slides: Neurology- Two cases of lower limb weakness.pdf – NMO Clinical Presentation slides [5] Senior notes: Ryan Ho Neurology.pdf – Section 6.1.2 Neuromyelitis Optica Spectrum Disorders [6] GC Lecture slides: GC 225. Neuroimmunological disorders of the central nervous system.pdf – NMOSD section, abbreviations, and MS DMT warning [7] GC Lecture slides: GC 225. Neuroimmunological disorders of the central nervous system.pdf – Table 1 IPND diagnostic criteria [8] Senior notes: Ryan Ho Opthalmology.pdf – Section 4.3.3 Optic Neuritis, footnote 42
Differential Diagnosis of NMOSD
Before diving into the list, understand why NMOSD can be confused with other conditions. NMOSD presents with three broad clinical syndromes — optic neuritis, myelitis, and brainstem dysfunction — and each of these syndromes has its own differential. The DDx therefore spans:
- Other CNS inflammatory demyelinating diseases (the closest mimics)
- Systemic autoimmune diseases with CNS involvement
- Infectious causes of optic neuritis or myelitis
- Vascular causes
- Other structural/compressive causes of myelopathy
The key discriminating features are the antibody profile (AQP4-IgG vs MOG-IgG vs neither), the MRI pattern (LETM vs short-segment; brain lesion distribution), the CSF findings (oligoclonal bands present or absent), and the clinical context (demographics, associated systemic disease, preceding infection).
DDx by Clinical Presentation
The patient presents with acute/subacute visual loss ± pain on eye movement. The question is: is this NMOSD, MS, MOGAD, or something else?
| Diagnosis | Key Distinguishing Features | Why it mimics NMOSD |
|---|---|---|
| Multiple sclerosis (MS) | Unilateral ON; good recovery; Uhthoff's phenomenon; OCBs positive (90%); periventricular Dawson's fingers on MRI [2] | Both cause inflammatory optic neuritis in young adults |
| MOGAD | Often bilateral ON; good recovery (better than NMOSD); MOG-IgG+; disc oedema prominent; may have concurrent ADEM in children [6] | Bilateral ON + myelitis overlap with NMOSD |
| Ischaemic optic neuropathy (AION) | Older patient; painless; altitudinal VF defect; a/w GCA (temporal headache, jaw claudication, ESR > 50) or vasculopathic RFs [9] | Both cause acute visual loss |
| Infectious ON: syphilis, HIV, TB | Specific serology; risk factors; may have other systemic features [8] | Can cause bilateral ON |
| SLE / Sjögren's | Systemic features (rash, arthritis, sicca); specific autoantibodies (anti-dsDNA, anti-Ro/La) [1][10] | CNS vasculitis can cause ON and myelitis |
| Sarcoidosis | Bilateral hilar lymphadenopathy on CXR; elevated ACE; non-caseating granulomas on biopsy; can affect optic nerve and meninges | Granulomatous ON can mimic inflammatory ON |
The patient presents with acute paraparesis, sensory level, and bladder dysfunction. The question is: is this NMOSD, MS, MOGAD, or a structural/compressive/vascular cause?
| Diagnosis | Key Distinguishing Features | Why it mimics NMOSD |
|---|---|---|
| MS | Short-segment myelitis (< 2 vertebral segments); eccentric/peripheral cord lesion on axial MRI; OCBs+ [2] | Both cause inflammatory myelitis |
| MOGAD | LETM possible but usually shorter than NMOSD; more conus/lower cord involvement; MOG-IgG+ [6] | LETM pattern can overlap |
| Transverse myelitis (idiopathic) | Monophasic; no AQP4 or MOG antibodies; diagnosis of exclusion [1] | Same acute spinal cord syndrome |
| Compressive myelopathy (cervical spondylosis, tumour, epidural abscess) | Progressive not relapsing; structural cause on MRI; may have radicular pain; no systemic inflammation | Presents with paraparesis and sensory level |
| Spinal cord infarction | Hyperacute onset (minutes, not hours-days); anterior spinal artery territory (spares dorsal columns); vascular RFs | Acute bilateral weakness mimics myelitis |
| Spinal dural AV fistula | Middle-aged male; progressive myelopathy; prominent flow voids on MRI; confirmed by spinal angiography | LETM-pattern T2 signal on MRI |
| SLE / CNS vasculitis | Multi-system disease; specific autoantibodies [1][10] | Can present as a recurrent neurologic syndrome before systemic manifestation occurs |
| Sarcoidosis | Subacute; dorsal cord predominance; leptomeningeal enhancement; elevated ACE | Can cause LETM |
| Intramedullary tumour (astrocytoma, ependymoma) | Progressive, not relapsing; mass effect; heterogeneous enhancement | T2 hyperintense expansile cord lesion |
| Vitamin B12 deficiency (subacute combined degeneration) | Dorsal column signs predominant (loss of proprioception/vibration); megaloblastic anaemia; low B12 | Bilateral spinal cord dysfunction |
Intractable hiccups, nausea, vomiting — often initially misdiagnosed as a GI problem.
| Diagnosis | Key Distinguishing Features |
|---|---|
| GI causes (GORD, gastroparesis, gastric outlet obstruction) | Responds to standard antiemetics; normal MRI brain |
| Raised ICP (tumour, hydrocephalus) | Headache, papilloedema, morning vomiting, focal neurological signs |
| Brainstem stroke (lateral medullary / Wallenberg syndrome) | Hyperacute onset; ipsilateral Horner's, facial pain, cerebellar signs, contralateral spinothalamic loss |
| Brainstem tumour | Progressive; other cranial nerve palsies |
| NMOSD | Key clue: intractable hiccups/vomiting NOT responding to antiemetics + MRI showing dorsal medullary lesion + AQP4-IgG+ |
The "Big Three" Closest Mimics — In Depth
These three conditions are the most commonly confused with NMOSD and most likely to appear in exams:
This is the single most important differential. The GC lecture slide explicitly lists NMOSD as a DDx of MS, and vice versa [6].
| Feature | NMOSD | MS |
|---|---|---|
| Serology | Anti-AQP4 (NMO-IgG) | Negative |
| CSF | Pleocytosis, no OCBs | WBC < 25, OCBs positive (90%) |
| MRI brain | Atypical changes (50%), brainstem lesions | Periventricular Dawson's fingers, ovoid perpendicular to ventricles |
| MRI spine | LETM ≥ 3 segments | Short segment, peripheral/eccentric |
| ON | Bilateral, severe | Unilateral, good recovery |
| INO | No INO | Classic (bilateral INO) |
| Pathology | Astrocytopathy → secondary demyelination + necrosis | Primary demyelination, relative axonal sparing |
Why this matters clinically: Disease-modifying drugs for MS (beta-IFN, DMF, fingolimod, natalizumab, alemtuzumab) should NOT be used in NMOSD: ineffective/worsen disease [6]. Misdiagnosing NMOSD as MS and starting MS-specific DMTs can precipitate devastating relapses.
CRITICAL Exam Point — Distinguishing NMOSD from MS
The two most discriminating investigations are: (1) AQP4-IgG serology — positive in NMOSD, negative in MS; (2) CSF oligoclonal bands — absent in NMOSD, present in 90% of MS. Always order both when evaluating a patient with CNS inflammatory demyelinating disease.
MOGAD is the newest member of the CNS inflammatory demyelinating diseases triad [6]. It was previously lumped with NMOSD but is now recognised as a separate entity with its own antibody (MOG-IgG), pathology, and prognosis.
| Feature | NMOSD (AQP4-IgG+) | MOGAD (MOG-IgG+) |
|---|---|---|
| Antibody | AQP4-IgG | MOG-IgG |
| Target | Astrocyte foot processes (AQP4) | Outermost myelin sheath surface (MOG on oligodendrocytes) |
| Pathology | Astrocytopathy → secondary demyelination | Primary demyelination (oligodendrocytopathy) |
| Age | Adults (30s–50s) | Children and young adults |
| ON severity | Severe, poor recovery | Moderate-severe, but better recovery |
| ON features | Long optic nerve lesion, may extend to chiasm | Prominent disc oedema, perineural enhancement |
| Myelitis | LETM (≥3 segments), central cord | LETM possible, but may be shorter; conus preference |
| Brain | Periependymal lesions | ADEM-like lesions (large, fluffy, bilateral) |
| Course | > 90% relapsing | ~50% monophasic, ~50% relapsing |
| Prognosis | Poor — stepwise deterioration | Better — less residual disability |
| CSF | No OCBs | No OCBs |
| Treatment | Immunosuppression | Immunosuppression (similar, but may differ) |
Why does this matter? Because MOGAD has a generally better prognosis, and some patients may not need long-term immunosuppression if monophasic. In contrast, AQP4+ NMOSD almost always needs lifelong immunosuppression.
SLE can present as a recurrent neurologic syndrome before systemic manifestation occurs [1]. This is critical because:
- SLE can cause optic neuritis, transverse myelitis, and brainstem syndromes — directly mimicking NMOSD
- Some SLE patients are AQP4-IgG positive (overlap syndrome)
- In Hong Kong (high SLE prevalence in Chinese women), this is a realistic clinical scenario
Distinguishing clues: Look for systemic features (malar rash, arthritis, serositis, renal disease), check ANA, anti-dsDNA, complement levels (C3/C4), anti-phospholipid antibodies.
The GC lecture slide [6] provides an explicit DDx list that is extremely high-yield for exams:
DDx of multiple sclerosis (and by extension NMOSD):
- Neuromyelitis optica spectrum disorders (NMOSD)
- Myelin oligodendrocyte glycoprotein antibody associated disorders (MOGAD)
- Vasculitis (primary CNS angiitis / secondary such as SLE, Sjögren's syndrome)
- Acute disseminated encephalomyelitis (ADEM): post-viral
- Neuro-Behçet's disease
- Neurosyphilis
- Neuroborreliosis (Lyme disease)
- Leukodystrophies: genetic
- CADASIL: genetic
Let's briefly explain each of the less common ones:
| Condition | Key Features | Why on DDx |
|---|---|---|
| ADEM | Post-viral; monophasic; children > adults; large fluffy bilateral brain lesions; encephalopathy | Can present with ON + myelitis |
| Neuro-Behçet's disease | Oral/genital ulcers, uveitis, pathergy; brainstem predominant; meningoencephalitis | Relapsing CNS inflammation in young adults |
| Neurosyphilis | Exposure hx; Argyll Robertson pupils (small, irregular, accommodate but don't react to light); positive VDRL/RPR, FTA-ABS | Can cause ON, myelitis, meningitis |
| Neuroborreliosis (Lyme) | Tick bite hx; erythema migrans rash; CN VII palsy; radiculopathy; endemic areas (US/Europe, rare in HK) | Cranial neuropathy + myelitis |
| Leukodystrophies | Genetic; progressive; childhood onset usually; symmetric white matter changes; no inflammatory CSF | Progressive white matter disease |
| CADASIL | Genetic (NOTCH3 mutation); migraine with aura; subcortical infarcts; temporal pole white matter changes; family history | Multiple white matter lesions on MRI |
| Primary CNS angiitis | Headache, encephalopathy, strokes; multifocal lesions; diagnosis by angiography or brain biopsy | Multifocal CNS lesions, relapsing |
| Sjögren's syndrome | Sicca symptoms (dry eyes, dry mouth); anti-Ro/La+; can cause myelitis, ON | Autoimmune overlap with NMOSD |
| Investigation | NMOSD | MS | MOGAD | SLE | ADEM |
|---|---|---|---|---|---|
| AQP4-IgG | Positive (60-80%) | Negative | Negative | Occasionally + (overlap) | Negative |
| MOG-IgG | Negative | Negative | Positive | Negative | May be + in children |
| CSF OCBs | Absent | Present (90%) | Usually absent | Variable | Usually absent |
| CSF cells | Pleocytosis (may include neutrophils) | WBC < 25 | Pleocytosis | Variable | Pleocytosis |
| MRI spine | LETM ≥ 3 segments | Short segment | Variable, may be LETM | Variable | Multifocal |
| MRI brain | Periependymal, area postrema, hypothalamic | Dawson's fingers, periventricular | ADEM-like, cortical | Small vessel ischaemic changes | Large, bilateral, fluffy |
| ANA/anti-dsDNA | May co-exist (autoimmune clustering) | Negative | Negative | Positive | Negative |
A 42-year-old Chinese woman presents with bilateral visual loss over 3 days with pain on eye movement. Two years ago she had an episode of paraparesis with urinary retention that partially recovered. MRI spine then showed a T2 hyperintense lesion from C3 to T2.
Thought process:
- Bilateral ON → not typical MS (usually unilateral) → think NMOSD or MOGAD
- LETM C3–T2 = 8 segments → not MS (short segment) → strongly suggests NMOSD
- Chinese female, age 42 → epidemiology fits NMOSD (Asian, female, late 30s–50s)
- Relapsing course (ON now + myelitis 2 years ago) → NMOSD > 90% relapsing
- Must test: AQP4-IgG (expect positive), MOG-IgG (if AQP4 negative), CSF (expect no OCBs, pleocytosis), ANA/anti-dsDNA (rule out SLE overlap)
High Yield — DDx Summary for NMOSD
The three closest mimics of NMOSD are MS, MOGAD, and SLE. The key discriminators are: (1) AQP4-IgG — positive in NMOSD, negative in the others (SLE may rarely overlap); (2) CSF OCBs — absent in NMOSD, present in 90% of MS; (3) MRI spine pattern — LETM ≥3 segments in NMOSD vs short segments in MS; (4) ON laterality — bilateral in NMOSD vs unilateral in MS. Always test for both AQP4-IgG and MOG-IgG in any patient with CNS inflammatory demyelinating disease, especially before starting treatment (since MS-specific DMTs are contraindicated in NMOSD).
Active Recall - Differential Diagnosis of NMOSD
References
[1] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf – Section III Etiology, Differential diagnosis [2] Senior notes: Maksim Medicine Notes.pdf – Section 11.8 CNS demyelinating diseases, MS vs NMOSD table [5] Senior notes: Ryan Ho Neurology.pdf – Section 6.1.2 Neuromyelitis Optica Spectrum Disorders [6] GC Lecture slides: GC 225. Neuroimmunological disorders of the central nervous system.pdf – DDx of MS slide, NMOSD section, abbreviations [8] Senior notes: Ryan Ho Opthalmology.pdf – Section 4.3.3 Optic Neuritis, causes and footnote 42 [9] AOS material: AOS - Ophthalmology (Ans:Notes).pdf – Patient 2 AAION discussion [10] Senior notes: learning_points_output.txt – Neurology: Two Cases of Lower Limb Weakness learning points
Diagnostic Criteria, Diagnostic Algorithm, and Investigations for NMOSD
1. Diagnostic Criteria — 2015 International Panel for NMO Diagnosis (IPND) Criteria
These are the current gold-standard criteria used worldwide for diagnosing NMOSD. The GC lecture slide explicitly references Table 1: Core Clinical Characteristics and Diagnostic Criteria for NMOSD [6][7].
The fundamental logic of the criteria is:
- If AQP4-IgG is positive → you need much less clinical evidence (just one core clinical characteristic), because the antibody is so specific it essentially clinches the diagnosis
- If AQP4-IgG is negative or unknown → you need more clinical evidence (at least two core characteristics + additional MRI requirements), because without the antibody you need stronger phenotypic support
These are the six "building blocks" of the diagnosis [6][7]:
| # | Core Clinical Characteristic | Explanation |
|---|---|---|
| 1 | Optic neuritis | Inflammation of optic nerve → visual loss, pain on eye movement |
| 2 | Acute myelitis | Spinal cord inflammation → paraparesis, sensory level, bladder dysfunction |
| 3 | Area postrema syndrome | Unexplained hiccups or nausea/vomiting (lasting > 48 hours) |
| 4 | Acute brainstem syndrome | Other brainstem dysfunction (not area postrema alone) |
| 5 | Symptomatic narcolepsy or acute diencephalic syndrome | With diencephalic (hypothalamic/thalamic) MRI lesions |
| 6 | Symptomatic cerebral syndrome | With typical NMOSD brain lesions |
For AQP4-IgG seropositive NMOSD [5][6][7]:
All three of the following must be met:
- At least one core clinical characteristic
- Positive AQP4-IgG (using best available detection method — cell-based assay preferred)
- Exclusion of alternative diagnoses
Why is only one core feature needed? Because NMO-IgG has 100% specificity [5] — a positive result in the right clinical context is essentially diagnostic. The false-positive rate is negligible when using modern cell-based assays.
For AQP4-IgG seronegative (or status unknown) NMOSD [5][6][7]:
All four of the following must be met:
- At least two different core clinical characteristics occurring as one or more clinical attacks, of which at least one must be optic neuritis, myelitis with LETM, or area postrema syndrome
- Dissemination in space (two or more different core characteristics)
- Additional MRI requirements fulfilled (see below)
- Negative AQP4-IgG (or testing unavailable) + exclusion of alternative diagnoses
Additional MRI requirements for seronegative NMOSD:
| Core Characteristic | Required MRI Finding |
|---|---|
| Optic neuritis | MRI showing: (a) normal brain MRI OR only non-specific white matter lesions, OR (b) optic nerve MRI with T2-hyperintense lesion or T1-Gd-enhancing lesion extending over > 1/2 optic nerve length or involving optic chiasm |
| Acute myelitis | MRI showing: intramedullary lesion extending over ≥3 contiguous segments (LETM) OR ≥3 contiguous segments of focal spinal cord atrophy in patients with prior myelitis |
| Area postrema syndrome | MRI showing: dorsal medulla/area postrema lesion |
| Acute brainstem syndrome | MRI showing: periependymal brainstem lesion |
Why stricter criteria for seronegative patients?
Without the highly specific AQP4-IgG to anchor the diagnosis, you could be dealing with MS, MOGAD, or other mimics. Requiring two core features + specific MRI patterns increases diagnostic certainty and reduces misclassification. This is especially important because MS DMTs (beta-IFN, DMF, fingolimod, natalizumab, alemtuzumab) should NOT be used in NMOSD [6] — so getting the diagnosis right has direct treatment implications.
| AQP4-IgG Seropositive | AQP4-IgG Seronegative / Unknown | |
|---|---|---|
| Core clinical characteristics needed | ≥1 (any) | ≥2 (at least 1 must be ON, myelitis, or area postrema) |
| AQP4-IgG | Positive | Negative / unavailable |
| Additional MRI requirements | Not required | Required (specific to each core feature) |
| Dissemination in space | Not required | Required |
| Exclusion of alternative diagnoses | Yes | Yes |
The clinical approach to a patient suspected of NMOSD proceeds in a stepwise fashion: clinical assessment → antibody testing → MRI → CSF → exclusion of mimics.
Parallel investigations to run at the same time:
3. Investigation Modalities — In Detail
3.1 Serum Antibody Testing
Blood for anti-AQP4 antibodies [4]
| Aspect | Detail |
|---|---|
| What it detects | IgG1 antibodies against aquaporin-4 water channels on astrocyte foot processes |
| Sensitivity | ~72% [5] (i.e. 20-30% of true NMOSD patients are seronegative) |
| Specificity | ~100% [5] — a positive result is essentially diagnostic |
| Preferred assay | Cell-based assay (CBA) — live or fixed cells transfected with human AQP4; superior to ELISA or immunofluorescence |
| When to test | At presentation; ideally before immunotherapy (steroids/PLEX can lower titres) |
| Titres | May correlate with disease activity; useful for monitoring but not for diagnosis |
Why is the CBA preferred? Because AQP4 is a transmembrane protein that must be in its native conformation (embedded in a cell membrane) to be properly recognised by the antibody. Older assays (ELISA, tissue-based immunofluorescence) present denatured or fragmented AQP4, missing some antibodies. The CBA preserves the 3D structure → higher sensitivity.
Practical Exam Point
A negative AQP4-IgG does NOT exclude NMOSD. If clinical suspicion is high, consider: (1) repeat testing (seroconversion can occur), (2) test MOG-IgG (may be MOGAD instead), (3) apply seronegative NMOSD criteria. Same treatment for seropositive and seronegative NMOSD [5].
| Aspect | Detail |
|---|---|
| What it detects | IgG1 antibodies against myelin oligodendrocyte glycoprotein on the outermost myelin surface |
| Role in NMOSD workup | To differentiate AQP4-negative patients: if MOG-IgG+ → MOGAD (a separate entity, not NMOSD) [6] |
| Assay | Cell-based assay (essential — ELISA unacceptable due to high false-positive rate) |
Autoimmune markers: ANA, anti-dsDNA, anti-ENA, C3, C4, ANCA, anti-AChR Ab [4]
| Test | Purpose |
|---|---|
| ANA, anti-dsDNA, C3/C4 | Exclude SLE (which can mimic NMOSD and occasionally co-exists) |
| Anti-Ro/La (anti-ENA) | Exclude Sjögren's syndrome |
| ANCA | Exclude CNS vasculitis |
| Anti-AChR | Myasthenia gravis can co-exist with NMOSD (autoimmune clustering) |
Why screen for autoimmune diseases? Because NMOSD frequently co-exists with other autoimmune conditions. Finding concurrent SLE or Sjögren's doesn't exclude NMOSD — it may be an overlap syndrome — but it changes your management approach (treat both).
CSF: inflammatory profiles [4][5]
| CSF Parameter | Expected Finding in NMOSD | Explanation |
|---|---|---|
| Cell count | Pleocytosis (↑WBC) [2][5] — typically 5–50 cells/μL | Reflects active CNS inflammation; may include monocytes, lymphocytes, and occasionally neutrophils (unusual in MS) |
| Differential | Usually monocyte/lymphocyte, occasionally neutrophil [5] | Neutrophilic predominance is a clue to NMOSD over MS (which is purely lymphocytic) |
| Protein | Mildly elevated | Non-specific; reflects BBB breakdown |
| Glucose | Normal | Helps exclude infections (bacterial meningitis → low glucose) |
| Oligoclonal bands | Absent (or present in only ~30%) [2][4] | This is a crucial distinguishing feature from MS (OCBs positive in > 85% of MS [4]) |
| Microbiology | Negative | Must exclude infectious myelitis/encephalitis: bacterial culture, AFB, TB culture, viral studies [11] |
| Cytology | Normal | Exclude malignancy (leptomeningeal carcinomatosis, CNS lymphoma) |
"CSF: inflammatory profiles (oligoclonal bands in ~30%, vs. > 85% in patients with multiple sclerosis), microbiological workup to exclude infective causes" [4]
3.3 MRI — The Cornerstone of Imaging
MRI is the single most important imaging modality. You need both brain and spine imaging, with and without gadolinium (Gd) contrast.
MRI spine: LETM involving ≥3 segments [5]
| Timing | MRI Finding | Pathophysiological Explanation |
|---|---|---|
| Acute phase | ↑T2-weighted signal, central cord predominance, with Gd enhancement [5] | AQP4 concentrated around the central canal → astrocyte destruction → oedema and inflammation → T2 hyperintensity; Gd enhancement reflects BBB breakdown and active inflammation |
| Chronic phase | Longitudinal extensive cord atrophy ± T2 signal changes [5] | Completed astrocyte/axonal destruction → tissue loss → cord atrophy (irreversible) |
Key features that distinguish NMOSD myelitis from MS myelitis on MRI:
| Feature | NMOSD | MS |
|---|---|---|
| Length | ≥3 contiguous vertebral segments (LETM) [2][5] | Short segments (usually < 2) [2] |
| Cross-sectional location | Central cord (grey matter predominance) | Peripheral/eccentric (white matter predominance) |
| Swelling | Often expansile (cord swelling) | Usually not expansile |
| Enhancement | Patchy or ring-like Gd enhancement | Incomplete ring enhancement |
| Chronic | Cord atrophy (extensive) | Cord atrophy (focal) |
Why central cord in NMOSD? AQP4 is most densely expressed on astrocytes surrounding the central canal and in the grey matter of the spinal cord. So when AQP4-IgG attacks, the destruction starts centrally and extends outward → central cord predominance on axial MRI.
Why LETM (≥3 segments)? Because AQP4 is distributed continuously along the central canal. Unlike MS, where focal perivascular plaques produce discrete short lesions, the autoimmune attack in NMOSD spreads along the continuous distribution of AQP4-expressing astrocytes → longitudinally extensive lesion.
MRI brain findings in NMOSD [2]:
| Finding | Frequency | Location / Pattern |
|---|---|---|
| Atypical brain changes | ~50% | Not in the typical MS pattern (no Dawson's fingers) |
| Brainstem lesions | ~15% | Dorsal medulla (area postrema), periependymal brainstem |
| Periependymal lesions | Variable | Around lateral ventricles, 3rd ventricle, aqueduct — reflects AQP4 concentration on ependymal astrocytes |
| Hypothalamic/diencephalic lesions | Rare | Symptomatic narcolepsy, endocrine dysfunction |
| Large hemispheric lesions | Rare | Can be tumefactive; may mimic ADEM or tumour |
How is this different from MS brain MRI?
| MS Brain MRI | NMOSD Brain MRI |
|---|---|
| Periventricular lesions (Dawson's fingers) — ovoid lesions perpendicular to ventricles [12] | Periependymal lesions — but NOT Dawson's fingers pattern |
| Juxtacortical lesions | Rare cortical involvement |
| Infratentorial lesions | Dorsal medullary / area postrema lesions (pathognomonic location) |
| Corpus callosum lesions | Not characteristic |
| Small, well-defined | May be larger, less defined, cloud-like |
Inflammatory changes involving the optic nerves / optic chiasm [4]
| Finding | Significance |
|---|---|
| T2 hyperintensity of optic nerve | Active optic neuritis |
| Gd enhancement of optic nerve | Active inflammation |
| Long optic nerve lesion (> 1/2 nerve length) | More suggestive of NMOSD than MS (MS lesions are shorter) |
| Involvement of optic chiasm | Highly suggestive of NMOSD (very rare in MS) |
| Bilateral optic nerve involvement | More suggestive of NMOSD |
3.4 Additional Investigations
| Aspect | Detail |
|---|---|
| What it tests | Speed of electrical conduction along the optic nerve |
| Finding in NMOSD | Delayed P100 latency — indicates demyelination of the optic nerve |
| Comparison | VEP delay is also seen in MS; does not distinguish the two |
| Clinical use | Confirms subclinical optic nerve involvement; supports diagnosis of ON even if MRI equivocal |
"Evoked potentials are electrical events generated in CNS by peripheral stimulation of a sensory organ. Evoked potentials are delayed in MS patients" [12] — this principle applies equally to NMOSD-related optic neuritis.
| Aspect | Detail |
|---|---|
| What it measures | Retinal nerve fibre layer (RNFL) thickness — a proxy for axonal loss in the optic nerve |
| Finding in NMOSD | Significant RNFL thinning after ON attacks — typically more severe than MS |
| Clinical use | Quantitative assessment of optic nerve damage; can track disease progression; supports severity assessment |
Bloods to order in the workup of a spinal cord lesion [11]:
| Test | Purpose |
|---|---|
| CBC, ESR, CRP | Screen for infection, inflammation |
| LRFT, glucose | Baseline, exclude metabolic causes |
| B12, folate | Exclude subacute combined degeneration (mimics myelopathy) |
| VDRL | Exclude neurosyphilis |
| HIV | Exclude HIV-related myelopathy or ON |
| ANA, anti-dsDNA | Exclude SLE |
| SPE (serum protein electrophoresis) | Exclude myeloma/paraproteinaemia |
| Blood cultures | Exclude septicaemia/epidural abscess |
| PSA (in males) | Exclude spinal metastasis |
The table below summarises how investigations help you distinguish NMOSD from its key mimics:
| Investigation | NMOSD | MS | MOGAD | SLE |
|---|---|---|---|---|
| AQP4-IgG | Positive (60-80%) | Negative | Negative | Occasionally + |
| MOG-IgG | Negative | Negative | Positive | Negative |
| CSF OCBs | Absent | Present (90%) | Usually absent | Variable |
| CSF cells | Pleocytosis ± neutrophils | WBC < 25 | Pleocytosis | Variable |
| MRI spine | LETM ≥3 segments, central | Short segment, peripheral | Variable length, conus | Variable |
| MRI brain | Periependymal, area postrema | Dawson's fingers, periventricular | ADEM-like, fluffy | Small vessel changes |
| MRI optic nerve | Long lesion, may involve chiasm | Short lesion | Perineural enhancement | Variable |
| ANA / anti-dsDNA | May co-exist | Negative | Negative | Positive |
| VEP | Delayed P100 | Delayed P100 | Delayed P100 | Variable |
High Yield Diagnostic Summary
To diagnose NMOSD you need:
- Clinical: ≥1 core characteristic (if AQP4+) or ≥2 (if AQP4−)
- Serology: AQP4-IgG (100% specific, 72% sensitive [5]) — cell-based assay preferred
- MRI spine: LETM ≥3 segments, central cord, Gd-enhancing acutely [5]
- MRI brain/orbits: optic nerve/chiasm lesions; area postrema or periependymal brain lesions [4]
- CSF: Pleocytosis, NO oligoclonal bands [2][4]
- Exclude: MS (OCBs+, short segments), MOGAD (MOG-IgG+), SLE (ANA+), infections (VDRL, HIV)
NMO-IgG: 100% specificity, 72% sensitivity — same treatment for seropositive and seronegative [5]
Active Recall - NMOSD Diagnostic Criteria, Algorithm and Investigations
References
[2] Senior notes: Maksim Medicine Notes.pdf – Section 11.8 CNS demyelinating diseases, MS vs NMOSD table [4] Lecture slides: Neurology- Two cases of lower limb weakness.pdf – NMO investigations and treatment slide, investigations overview slides [5] Senior notes: Ryan Ho Neurology.pdf – Section 6.1.2 Neuromyelitis Optica Spectrum Disorders [6] GC Lecture slides: GC 225. Neuroimmunological disorders of the central nervous system.pdf – NMOSD section, MS DMT warning, abbreviations [7] GC Lecture slides: GC 225. Neuroimmunological disorders of the central nervous system.pdf – Table 1 IPND diagnostic criteria [8] Senior notes: Ryan Ho Opthalmology.pdf – Section 4.3.3 Optic Neuritis [11] Senior notes: Maksim Medicine Notes.pdf – Section 11.10 Approach to acute spinal cord syndrome, investigation bloods [12] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf – Section VII Diagnosis, McDonald criteria, MRI and CSF findings
Management Algorithm and Treatment Modalities for NMOSD
NMOSD management is conceptually divided into three pillars:
- Acute attack treatment — rescue therapy to halt ongoing inflammation and limit permanent damage
- Long-term relapse prevention — maintenance immunosuppression to prevent future attacks (this is the cornerstone of NMOSD care, since > 90% have a relapsing course [2][5] and each attack causes stepwise deterioration with significant residual deficits [5])
- Supportive and rehabilitative care — managing symptoms and disabilities accumulated from prior attacks
The single most critical management principle, hammered home across every source:
Disease-modifying drugs for MS (beta-IFN, DMF, fingolimod, natalizumab, alemtuzumab) should NOT be used in NMOSD: ineffective/worsen disease [6]
Why do MS drugs worsen NMOSD? Because the pathophysiology is fundamentally different:
- MS is primarily T-cell driven → MS DMTs modulate T-cell trafficking (natalizumab blocks α4-integrin on T-cells; fingolimod traps lymphocytes in lymph nodes via S1P receptor modulation)
- NMOSD is primarily humoral (B-cell / complement-mediated astrocytopathy) → blocking T-cell trafficking is irrelevant and may paradoxically enhance humoral immune responses
- Fingolimod and natalizumab have been reported to trigger severe NMOSD relapses, sometimes fatal
- Interferon-beta can increase AQP4-IgG production and worsen inflammation in NMOSD
This is why establishing the correct diagnosis (NMOSD vs MS) before starting long-term therapy is absolutely essential.
1. Acute Attack Treatment
The goal is to rapidly suppress inflammation to prevent irreversible astrocyte destruction, demyelination, and axonal loss. Every hour of untreated active inflammation = more permanent damage.
Acute: IV methylprednisolone [4][5]
| Aspect | Detail |
|---|---|
| Regimen | IV methylprednisolone 1g/day for 3–5 days |
| Mechanism | High-dose glucocorticoids suppress inflammation at multiple levels: (1) inhibit T-cell and B-cell activation, (2) reduce pro-inflammatory cytokine production (IL-1, IL-6, TNF-α), (3) stabilise the blood-brain barrier (reduce oedema and immune cell infiltration), (4) induce lymphocyte apoptosis |
| Onset of action | Hours to days; clinical improvement usually begins within 3–5 days |
| Follow-up | Followed by oral prednisolone taper (typically starting at 1mg/kg/day, tapering over weeks to months) to prevent rebound inflammation |
| Side effects | Hyperglycaemia (monitor BSL), insomnia, GI irritation (co-prescribe PPI), hypertension, infection risk, avascular necrosis (rare with short courses), psychosis (rare) |
Why pulse steroids first? They are immediately available, fast-acting, broadly immunosuppressive, and have decades of evidence in CNS inflammatory disease. They are the universal first step in any acute CNS demyelinating attack (NMOSD, MS, MOGAD, ADEM).
| Aspect | Detail |
|---|---|
| Indication | Steroid-refractory attacks OR severe attacks where rapid antibody removal is needed (especially severe myelitis or bilateral ON with near-blindness) |
| Regimen | Typically 5–7 exchanges over 10–14 days |
| Mechanism | Physically removes circulating AQP4-IgG antibodies, complement components, and inflammatory mediators from the plasma. The patient's plasma is separated from blood cells, discarded, and replaced with albumin or fresh frozen plasma |
| Why it works especially well in NMOSD | Because NMOSD is a humoral, antibody-mediated disease — the pathogenic antibody (AQP4-IgG) is in the circulation. Removing it directly reduces the effector mechanism. This is unlike MS, where the pathology is more T-cell driven and less dependent on circulating antibodies |
| Side effects | Hypotension, hypocalcaemia (from citrate anticoagulant), coagulopathy (removal of clotting factors), line-related complications (infection, thrombosis), allergic reactions |
| Practical note | Requires central venous access; limited availability in some centres |
When to use PLEX early
In practice, many centres now use PLEX alongside IV steroids from the start (rather than sequentially) in severe NMOSD attacks — especially bilateral ON threatening blindness or cervical myelitis with respiratory compromise. The rationale is that NMOSD attacks are more severe than MS attacks, and early aggressive treatment limits irreversible damage. Don't wait for steroids to "fail" if the attack is catastrophic.
Acute: IVIg (for NMOSD) [2][5]
| Aspect | Detail |
|---|---|
| Indication | Steroid-refractory + PLEX-refractory attacks, or when PLEX is unavailable/contraindicated |
| Regimen | IVIg 0.4g/kg/day for 5 days (total 2g/kg) |
| Mechanism | Multiple mechanisms: (1) Fc receptor blockade (saturates Fc receptors on macrophages, reducing antibody-dependent destruction), (2) anti-idiotypic antibodies neutralise pathogenic autoantibodies, (3) complement consumption/blocking, (4) modulation of cytokine production |
| Side effects | Headache, nausea, fever, anaphylaxis (especially in IgA-deficient patients), renal impairment (sucrose-containing preparations), thromboembolic events (rare), aseptic meningitis |
| Practical note | Easier to administer than PLEX (peripheral IV access sufficient); available in most hospitals |
2. Long-Term Relapse Prevention (Maintenance Immunosuppression)
This is the most important aspect of NMOSD management. Since > 90% of patients have a relapsing course [2][5] and attacks often lead to 25–50% mortality with significant residual deficits [5], all patients with confirmed NMOSD should be started on long-term immunosuppression after the first attack.
Prevention of relapses: Long-term immunosuppression [4]
2A. Traditional First-Line Agents
| Aspect | Detail |
|---|---|
| Mechanism | Purine analogue → metabolised to 6-mercaptopurine → inhibits purine synthesis → suppresses proliferation of T-cells and B-cells. "Aza" = nitrogen; "thio" = sulphur; "purine" = purine base — it's a sulphur-containing purine analogue that tricks the cell into using faulty DNA building blocks |
| Dose | 2–3 mg/kg/day orally |
| Onset | Slow: takes 3–6 months for full effect → overlap with oral prednisolone taper during this period |
| Monitoring | FBC (risk of myelosuppression — check WBC and lymphocyte count), LFT (hepatotoxicity), TPMT genotype before starting (thiopurine methyltransferase deficiency → excessive drug levels → severe myelosuppression) |
| Side effects | Myelosuppression (leucopenia, thrombocytopenia), hepatotoxicity, nausea, increased infection risk, long-term lymphoma risk (small) |
| Advantages | Inexpensive, widely available, long track record |
| Contraindications | TPMT deficiency, pregnancy (relatively — category D, but sometimes continued with careful monitoring), active severe infection |
| Aspect | Detail |
|---|---|
| Mechanism | Inhibits inosine monophosphate dehydrogenase (IMPDH) — a key enzyme in the de novo purine synthesis pathway. Lymphocytes are uniquely dependent on de novo purine synthesis (unlike most cells which can use the salvage pathway), so MMF selectively suppresses lymphocyte proliferation |
| Dose | 1–1.5g BD (total 2–3g/day) |
| Onset | Faster than azathioprine: weeks to 2–3 months |
| Monitoring | FBC (lymphocyte count), LFT, renal function |
| Side effects | GI upset (diarrhoea, nausea — dose-limiting), myelosuppression, increased infection risk |
| Advantages | Better tolerated GI-wise for some patients cf azathioprine; no need for TPMT testing |
| Contraindications | Pregnancy (teratogenic — category X; must use effective contraception), active severe infection |
iii. IV Rituximab
| Aspect | Detail |
|---|---|
| Mechanism | Anti-CD20 monoclonal antibody → binds CD20 on the surface of B cells (pre-B cells through mature B cells, but NOT plasma cells) → complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity → B-cell depletion |
| Why it works in NMOSD | NMOSD is a B-cell and antibody-mediated disease. By depleting B cells, you remove: (1) the precursors that differentiate into AQP4-IgG-secreting plasma cells, (2) B cells that serve as antigen-presenting cells to T cells, (3) B cells that produce pro-inflammatory cytokines. Even though rituximab doesn't directly kill long-lived plasma cells, it depletes the B-cell pool that replenishes them |
| Dose | Induction: 1g IV on day 1 and day 15 (or 375 mg/m² weekly x 4); Maintenance: 1g IV every 6 months (or re-dose when CD19/CD20 B cells begin to repopulate) |
| Onset | Faster than azathioprine or MMF: B-cell depletion occurs within 2 weeks |
| Monitoring | CD19/CD20 count (monitor B-cell depletion), immunoglobulin levels (risk of hypogammaglobulinaemia with prolonged use), FBC, hepatitis B serology before starting (risk of reactivation) |
| Side effects | Infusion reactions (pre-medicate with paracetamol, antihistamine, and steroid), increased infection risk (especially if hypogammaglobulinaemia develops), progressive multifocal leukoencephalopathy (PML — very rare), hepatitis B reactivation |
| Advantages | Rapid onset, potent B-cell depletion, growing evidence base in NMOSD; increasingly used as first-line in many centres |
| Contraindications | Active hepatitis B (screen and treat/prophylax first), active severe infection, prior PML |
High Yield — Traditional vs Biologic First-Line
In HKUMed teaching, the three agents consistently listed for NMOSD relapse prevention are: oral azathioprine, mycophenolate mofetil, and IV rituximab [4][5]. In current clinical practice (2024–2026), rituximab is increasingly used as first-line in many centres due to faster onset and superior efficacy data. However, azathioprine and MMF remain important (cheaper, oral, widely available in resource-limited settings).
2C. Newer Targeted Therapies (2019–2025 Approvals)
Three newer biological agents have been approved for AQP4-IgG seropositive NMOSD based on landmark randomised controlled trials. These are increasingly important and likely to appear in exams as awareness grows:
| Aspect | Detail |
|---|---|
| Mechanism | Anti-C5 monoclonal antibody → blocks cleavage of complement C5 into C5a and C5b → prevents formation of the membrane attack complex (C5b-9 / MAC) → directly stops complement-mediated astrocyte lysis |
| Why it makes mechanistic sense | NMOSD pathology involves AQP4-IgG (IgG1) binding astrocytes → classical complement pathway activation → MAC formation → astrocyte lysis. Eculizumab blocks the terminal step of this pathway, preventing the final common pathway of cell destruction |
| Trial | PREVENT trial (2019): 94% reduction in relapse risk vs placebo in AQP4-IgG+ NMOSD |
| Side effects | Increased risk of meningococcal infection (C5 is critical for defence against Neisseria) → mandatory meningococcal vaccination before starting; headache, URTIs |
| Limitations | Extremely expensive; IV infusion every 2 weeks; only for AQP4-IgG+ patients |
The name tells you: "eculizumab" — "-lizumab" = humanised monoclonal antibody; "ecu-" = from the complement (C) system.
| Aspect | Detail |
|---|---|
| Mechanism | Anti-CD19 monoclonal antibody → depletes a broader range of B-lineage cells than rituximab (CD19 is expressed on pre-B cells, mature B cells, AND some plasmablasts/early plasma cells, unlike CD20 which spares plasma cells) |
| Why broader than rituximab? | CD19 is expressed more broadly across the B-cell lineage than CD20, including on antibody-secreting plasmablasts → inebilizumab may reduce AQP4-IgG production more effectively |
| Trial | N-MOmentum trial (2019): 77% reduction in attacks vs placebo in AQP4-IgG+ NMOSD |
| Side effects | Similar to rituximab: infection risk, infusion reactions, hypogammaglobulinaemia |
| Aspect | Detail |
|---|---|
| Mechanism | Anti-IL-6 receptor monoclonal antibody (recycling antibody technology) → blocks IL-6 signalling. IL-6 is a key cytokine that promotes: (1) B-cell differentiation into antibody-secreting plasma cells, (2) maintenance of plasmablasts that produce AQP4-IgG, (3) disruption of the BBB, (4) Th17 differentiation |
| Why IL-6? | IL-6 is markedly elevated in the CSF of NMOSD patients during attacks. It drives the humoral immune response that produces AQP4-IgG and promotes BBB breakdown, facilitating antibody entry into the CNS |
| Trial | SAkuraStar and SAkuraSky trials (2019–2020): significant reduction in relapses, especially in AQP4-IgG+ patients |
| Administration | Subcutaneous injection — more convenient than IV infusions |
| Side effects | Infection risk, injection site reactions; monitor LFTs and lipids (IL-6 blockade can cause hyperlipidaemia and transaminitis) |
"Satralizumab" — related to tocilizumab (also anti-IL-6R, used in RA), but engineered with antibody recycling technology for longer duration of action.
| Agent | Mechanism | Route | Onset | Key Side Effects | Special Considerations |
|---|---|---|---|---|---|
| Azathioprine | Purine synthesis inhibition | Oral | 3–6 months | Myelosuppression, hepatotoxicity | Check TPMT; cheap; need steroid bridge |
| MMF | IMPDH inhibition | Oral | Weeks–3 months | GI upset, myelosuppression | Teratogenic (pregnancy X); no TPMT needed |
| Rituximab | Anti-CD20 B-cell depletion | IV | 2 weeks | Infusion reactions, infections, HBV reactivation | Screen HBV; monitor CD19/IgG levels |
| Eculizumab | Anti-C5 complement blockade | IV q2w | Rapid | Meningococcal infection | Mandatory meningococcal vaccine; AQP4+ only |
| Inebilizumab | Anti-CD19 B-cell depletion | IV | 2 weeks | Infections, hypogammaglobulinaemia | Broader B-cell depletion than rituximab |
| Satralizumab | Anti-IL-6R | SC | Weeks | Infections, hyperlipidaemia | Convenient SC dosing; AQP4+ preferentially |
This cannot be overemphasised:
| Contraindicated Drug | Drug Class / Mechanism | Why Harmful in NMOSD |
|---|---|---|
| Beta-interferon (IFN-β) | Immunomodulator | May increase AQP4-IgG production; enhances humoral responses; reported to worsen NMOSD attacks |
| Dimethyl fumarate (DMF) | Nrf2 activator / anti-inflammatory | Ineffective; may worsen NMOSD |
| Fingolimod | S1P receptor modulator — traps lymphocytes in lymph nodes | Traps T-cells but may paradoxically release B-cells and enhance humoral immunity; documented severe NMOSD relapses |
| Natalizumab | Anti-α4-integrin — blocks T-cell migration across BBB | Blocks T-cell entry but does not prevent humoral (antibody/complement) attack; NMOSD relapses reported |
| Alemtuzumab | Anti-CD52 — depletes T and B cells | Rapid B-cell reconstitution after treatment may trigger a surge in AQP4-IgG production; worsening reported |
CRITICAL — MS DMTs in NMOSD
Disease-modifying drugs for MS (beta-IFN, DMF, fingolimod, natalizumab, alemtuzumab) should NOT be used in NMOSD: ineffective/worsen disease [6]. This is one of the most commonly tested points in HKUMed in-house exams. The mechanistic reason: NMOSD is antibody/complement-mediated (humoral), and MS drugs that modulate T-cell function do not address — and may even enhance — the humoral immune pathology of NMOSD.
Acute attack treatment and relapse prevention address the immunological disease, but many patients accumulate disability from prior attacks. Supportive care is essential:
| Domain | Management | Rationale |
|---|---|---|
| Neuropathic pain | Gabapentin, pregabalin, amitriptyline, duloxetine | Central neuropathic pain from spinal cord lesions |
| Spasticity | Baclofen, tizanidine, physiotherapy, botulinum toxin injections | UMN damage → increased tone |
| Bladder dysfunction | Intermittent self-catheterisation, anticholinergics (oxybutynin), urology referral | Neurogenic bladder from spinal cord lesions |
| Bowel dysfunction | Bowel regimen (fibre, laxatives, scheduled toileting) | Autonomic involvement |
| Visual rehabilitation | Low-vision aids, occupational therapy, magnifiers | Permanent visual loss from ON |
| Physiotherapy | Strengthening, gait training, balance exercises | Residual weakness from myelitis |
| Occupational therapy | Adaptive devices, home modifications | Functional independence |
| Psychological support | Counselling, CBT, support groups | Chronic relapsing illness with unpredictable attacks; depression and anxiety common |
| DVT prophylaxis | TED stockings, LMWH in immobilised patients | Immobility from paraparesis increases VTE risk |
| Respiratory monitoring | Monitor FVC serially in cervical myelitis | Phrenic nerve involvement (C3–5) → respiratory failure; may need ventilatory support |
| Vaccination | Update vaccinations before starting immunosuppression; meningococcal vaccine mandatory before eculizumab; avoid live vaccines on immunosuppression | Prevent opportunistic infections |
6. Management in Special Populations
- Pre-conception counselling is essential
- MMF is contraindicated in pregnancy (category X — teratogenic)
- Azathioprine is relatively safer and can be continued with monitoring (category D — used when benefit outweighs risk)
- Rituximab: discontinue at least 6 months before conception; B-cell depletion in the neonate is a concern
- Relapse risk: may increase postpartum → ensure immunosuppression is resumed promptly after delivery
- Acute relapses during pregnancy: IV steroids and PLEX can be used
- If NMOSD co-exists with SLE or Sjögren's syndrome, treat both conditions
- Shared immunosuppressive agents (azathioprine, MMF, rituximab) may address both
- Rheumatology co-management recommended
| Factor | Detail |
|---|---|
| Disease course | ≥ 90% relapsing [2][5] |
| Mortality | 25–50% mortality from attacks (especially respiratory failure from cervical myelitis) [5] |
| Disability | Stepwise deterioration [5]; significant residual deficits after each attack |
| Visual outcome | Many patients develop permanent significant visual impairment or blindness |
| Mobility | Many require walking aid or wheelchair within 5–10 years if untreated |
| With treatment | Relapse rates reduced by 70–95% with modern therapies; earlier treatment = better outcomes |
High Yield Management Summary
Acute attacks: IV methylprednisolone first → plasma exchange if refractory → IVIg as third-line [2][4][5]
Long-term relapse prevention: Oral azathioprine, mycophenolate mofetil, or IV rituximab [4][5]. Newer agents: eculizumab (anti-C5), inebilizumab (anti-CD19), satralizumab (anti-IL-6R) — all for AQP4-IgG+ NMOSD.
CONTRAINDICATED: Beta-IFN, DMF, fingolimod, natalizumab, alemtuzumab — MS-specific DMTs are ineffective and worsen disease in NMOSD [6].
Key principle: NMOSD is a humoral (B-cell/complement) disease → treatment targets B cells (rituximab, inebilizumab), complement (eculizumab), or humoral cytokines (satralizumab/anti-IL-6R). MS drugs that modulate T-cell trafficking are irrelevant and harmful.
Prognosis: > 90% relapsing, stepwise deterioration, 25–50% mortality per severe attack. Early aggressive immunosuppression is essential.
Active Recall - NMOSD Management
References
[2] Senior notes: Maksim Medicine Notes.pdf – Section 11.8 CNS demyelinating diseases, MS vs NMOSD table [4] Lecture slides: Neurology- Two cases of lower limb weakness.pdf – NMO treatment slide [5] Senior notes: Ryan Ho Neurology.pdf – Section 6.1.2 Neuromyelitis Optica Spectrum Disorders [6] GC Lecture slides: GC 225. Neuroimmunological disorders of the central nervous system.pdf – NMOSD section, MS DMT contraindication warning
Complications of NMOSD
To understand the complications of NMOSD, think about what the disease actually destroys and where it strikes. NMOSD is an autoimmune astrocytopathy [4] that causes demyelination + axonal degeneration [2] predominantly at three sites: the optic nerves, the spinal cord (LETM), and the brainstem (especially the area postrema). Complications arise from two sources:
- Disease-related complications — permanent damage accumulating from recurrent attacks at these predilection sites
- Treatment-related complications — adverse effects of the immunosuppressive agents used chronically
Because attacks are often more severe with 25–50% mortality and significant residual deficits [5] and the course is one of stepwise deterioration [5] with ≥ 90% relapsing [2][5], complications are common and progressive. Unlike MS where early relapses often recover well, NMOSD attacks frequently leave behind irreversible damage from the outset — because astrocyte destruction leads to necrosis, not just demyelination.
1. Disease-Related Complications
| Complication | Pathophysiology | Clinical Impact |
|---|---|---|
| Permanent visual impairment / blindness | Recurrent optic neuritis → cumulative axonal loss in the optic nerve. Each attack destroys astrocytes (AQP4-rich in optic nerve) → secondary demyelination and axonal degeneration → irreversible loss of retinal ganglion cell axons. Visual loss in NMOSD is generally more severe than MS [4][5][8] — because astrocyte necrosis causes more complete axonal destruction than the primary demyelination of MS, where remyelination can partially restore function | Significant proportion of NMOSD patients develop legal blindness (VA < 6/60 or worse) in one or both eyes within 5–10 years if untreated. Activities of daily living severely affected; loss of driving, reading, independence |
| Optic atrophy | End-stage of repeated optic neuritis → loss of nerve fibres → temporal pallor of the optic disc on fundoscopy [8]; retinal nerve fibre layer thinning on OCT | Irreversible; indicates permanent structural damage |
| Bilateral blindness | NMOSD optic neuritis is usually bilateral (simultaneous or rapidly sequential) [2][4] — unlike MS which is typically unilateral. When both optic nerves are damaged by successive attacks, the patient can become completely blind | Catastrophic disability; complete dependence |
Why is visual outcome worse in NMOSD than MS? In MS, optic neuritis causes primary demyelination of the optic nerve — oligodendrocyte precursors can partially remyelinate the nerve → good visual recovery in most cases. In NMOSD, the astrocyte is destroyed first (astrocytopathy) → the neurotrophic support for both myelin and axons is lost → necrotic lesion rather than purely demyelinating → poor or absent recovery.
| Complication | Pathophysiology | Clinical Impact |
|---|---|---|
| Permanent paraplegia / quadriplegia | Recurrent LETM attacks → cumulative destruction of corticospinal tracts bilaterally. LETM tends to be more complete than MS myelitis [5] → each attack produces more severe motor deficit. Longitudinal extensive cord atrophy [5] develops chronically | Wheelchair dependence; loss of hand function in cervical involvement |
| Spasticity | Upper motor neuron damage (corticospinal tracts) → loss of descending inhibition on spinal reflexes → velocity-dependent increase in muscle tone (clasp-knife pattern), clonus, hyperreflexia | Pain, contractures, impaired mobility, difficulty with transfers and hygiene |
| Neuropathic pain | Damage to spinothalamic tract and dorsal horn neurons in the spinal cord → deafferentation pain (central neuropathic pain). Also thalamic/brainstem involvement can cause central pain syndromes | Chronic, debilitating; often described as burning, shooting, or electric-shock-like; refractory to standard analgesics |
| Sensory loss | Destruction of spinothalamic and dorsal column pathways → permanent loss of pain/temperature and/or proprioception/vibration below the lesion level | Falls risk (proprioceptive loss → sensory ataxia); burns and injuries (pain insensitivity) |
| Complication | Pathophysiology | Clinical Impact |
|---|---|---|
| Bladder dysfunction [5] | LETM disrupts sacral parasympathetic outflow (S2–4) and/or pontine micturition centre connections → neurogenic bladder. Can manifest as: (1) detrusor overactivity (urgency, frequency, incontinence) or (2) detrusor underactivity (retention, overflow incontinence) | Recurrent UTIs (from incomplete emptying/catheterisation), urosepsis, renal impairment, social embarrassment, reduced quality of life |
| Bowel dysfunction | Disruption of sacral autonomic pathways → neurogenic bowel (constipation, faecal incontinence) | Constipation can be severe; faecal incontinence profoundly impacts dignity |
| Sexual dysfunction [1] | Disruption of sacral parasympathetic (S2–4) and sympathetic (T11–L2) pathways → erectile dysfunction in males, reduced genital sensation and anorgasmia | Often under-reported; significant impact on quality of life and relationships |
| Orthostatic hypotension | Disruption of sympathetic outflow from intermediolateral cell column in thoracic cord → impaired vasoconstriction on standing | Falls, syncope, worsens immobility |
| Complication | Pathophysiology | Clinical Impact |
|---|---|---|
| Respiratory failure | Cervical myelitis involving C3–C5 → destruction of phrenic nerve motor neuron cell bodies in the anterior horn → diaphragmatic paralysis. This is the most immediately life-threatening complication of an NMOSD attack [5] | May require intubation and mechanical ventilation; can be fatal if not recognised promptly. This is why FVC monitoring is essential in cervical myelitis |
| Recurrent respiratory infections | Combination of: (1) impaired cough reflex (intercostal and abdominal muscle weakness from thoracic cord lesions), (2) immobility → atelectasis, (3) immunosuppressive therapy → infection susceptibility | Pneumonia is a major cause of morbidity and mortality |
| Chronic ventilator dependence | Severe cervical cord necrosis → permanent loss of phrenic nerve function | Long-term ventilatory support; nursing home care |
Neurological Emergency — Cervical Myelitis with Respiratory Failure
Respiratory failure from cervical LETM is the most feared acute complication. The phrenic nerve (C3, 4, 5 — "C3, 4, 5 keep the diaphragm alive") motor neuron cell bodies sit in the anterior horn of the cervical cord. When LETM extends into the upper cervical cord, these neurons are destroyed → diaphragmatic paralysis. This can develop over hours. Always monitor FVC serially in any patient with cervical myelitis. If FVC drops below 15–20 mL/kg or < 1 L, prepare for intubation.
| Complication | Pathophysiology | Clinical Impact |
|---|---|---|
| Persistent area postrema dysfunction | Astrocyte destruction in the area postrema (chemoreceptor trigger zone at floor of 4th ventricle) → chronic intractable nausea/vomiting/hiccups | Malnutrition, dehydration, electrolyte disturbance, weight loss; may require NG/PEG feeding |
| Bulbar dysfunction | Medullary lesions affecting CN IX, X nuclei → dysphagia, dysarthria | Aspiration pneumonia risk; may need speech therapy assessment and modified diet; PEG tube in severe cases |
| Central hypoventilation | Damage to medullary respiratory centres → Ondine's curse (loss of automatic respiratory drive, especially during sleep) | Nocturnal hypoventilation → morning headaches, drowsiness, eventually respiratory arrest during sleep; may need non-invasive ventilation |
These are secondary to the motor disability from myelitis:
| Complication | Mechanism | Prevention |
|---|---|---|
| Venous thromboembolism (DVT / PE) | Virchow's triad: immobility (stasis) + possible dehydration (reduced flow) + inflammatory state (endothelial injury) | TED stockings, LMWH prophylaxis, early mobilisation |
| Pressure ulcers (decubitus) | Immobility + sensory loss (patient cannot feel pressure damage) → ischaemic necrosis of skin and soft tissue over bony prominences | Regular turning (q2h), pressure-relieving mattress, skin inspection, nutrition optimisation |
| Contractures | Spasticity + immobility → fixed shortening of muscles and tendons → joint deformity | Physiotherapy, stretching, splinting, botulinum toxin for severe spasticity |
| Osteoporosis | Disuse (reduced weight-bearing) + chronic steroid use → decreased bone density | Weight-bearing exercises where possible, calcium/vitamin D, bisphosphonates if indicated, DEXA monitoring |
| Muscle wasting | Disuse atrophy + denervation (in severe cord lesions with anterior horn involvement) | Physiotherapy, nutritional support |
| Complication | Mechanism |
|---|---|
| Depression | Chronic disabling illness with unpredictable relapses; loss of vision, mobility, independence; chronic pain; social isolation |
| Anxiety | Fear of next attack; uncertainty about prognosis; worry about blindness or paralysis |
| Fatigue | Central fatigue from CNS inflammation + medication side effects + deconditioning + depression |
| Cognitive impairment | Less common than in MS, but can occur with cerebral/diencephalic lesions; also secondary to pain, depression, medication effects |
NMOSD patients have an inherent tendency toward autoimmunity. Co-existing autoimmune conditions are complications in themselves and can compound morbidity:
| Associated Condition | Relevance |
|---|---|
| SLE | Nephritis, serositis, cytopenias — adds organ damage |
| Sjögren's syndrome | Sicca symptoms, peripheral neuropathy, renal tubular acidosis |
| Myasthenia gravis | Fatigable weakness — compounds NMOSD motor disability |
| Autoimmune thyroid disease | Hypo/hyperthyroidism — fatigue, metabolic derangement |
2. Treatment-Related Complications
All long-term immunosuppressive agents carry inherent risks. These are complications of the treatment, not the disease itself, but they are clinically inseparable from NMOSD management.
| Complication | Mechanism | Prevention / Monitoring |
|---|---|---|
| Opportunistic infections | Immunosuppression → reduced T-cell and/or B-cell function → susceptibility to bacterial, viral, fungal, and mycobacterial infections | Vaccination before starting therapy; prophylactic co-trimoxazole if lymphopenic; monitor for PJP, TB, HBV reactivation |
| Herpes zoster reactivation | Immunosuppression → reduced cellular immunity → VZV reactivation from dorsal root ganglia | Consider zoster vaccination (recombinant, non-live) before immunosuppression |
| Hepatitis B reactivation | B-cell depleting therapies (rituximab, inebilizumab) can trigger HBV reactivation in HBsAg+ or anti-HBc+ patients | Mandatory HBV screening before rituximab; antiviral prophylaxis (entecavir/tenofovir) if positive |
| Progressive multifocal leukoencephalopathy (PML) | JC virus reactivation under profound immunosuppression → destruction of oligodendrocytes → progressive white matter demyelination | Very rare with rituximab (more common with natalizumab — which is contraindicated in NMOSD anyway); monitor for new neurological symptoms |
| Agent | Key Complications |
|---|---|
| Azathioprine | Myelosuppression (leucopenia, thrombocytopenia — especially if TPMT-deficient), hepatotoxicity, pancreatitis, long-term lymphoma risk (small) |
| MMF | GI upset (dose-limiting diarrhoea), myelosuppression, teratogenicity (pregnancy category X — must not conceive on this drug) |
| Rituximab | Infusion reactions, hypogammaglobulinaemia (IgG depletion with prolonged use → recurrent sinopulmonary infections), HBV reactivation, late-onset neutropenia |
| Eculizumab | Meningococcal infection — C5 blockade removes the terminal complement pathway needed to kill encapsulated organisms, especially Neisseria meningitidis → mandatory meningococcal vaccination before starting |
| Corticosteroids (chronic use) | Cushing's syndrome, osteoporosis, avascular necrosis, hyperglycaemia/diabetes, cataracts, glaucoma, adrenal suppression, weight gain, mood disturbance, skin thinning |
Treatment Complication to Remember — Eculizumab and Meningococcal Infection
Eculizumab blocks C5, preventing MAC formation. The MAC is essential for killing Neisseria species (encapsulated gram-negative diplococci). Patients on eculizumab have a dramatically increased risk of meningococcal meningitis and septicaemia. Meningococcal vaccination (MenACWY + MenB) is mandatory at least 2 weeks before the first dose. Some centres also provide prophylactic antibiotics (penicillin V or ciprofloxacin).
| Complication | Mechanism |
|---|---|
| Severe disease exacerbation from MS DMTs | Disease-modifying drugs for MS (beta-IFN, DMF, fingolimod, natalizumab, alemtuzumab) should NOT be used in NMOSD: ineffective/worsen disease [6]. Misdiagnosis of NMOSD as MS → starting MS-specific DMTs → severe relapses, sometimes fatal. Fingolimod and natalizumab are particularly dangerous. This is arguably the most preventable yet devastating complication in NMOSD care |
| System | Complications |
|---|---|
| Visual | Permanent visual impairment, bilateral blindness, optic atrophy |
| Motor | Paraplegia/quadriplegia, spasticity, contractures |
| Sensory | Neuropathic pain, sensory loss, sensory ataxia |
| Autonomic | Neurogenic bladder (UTIs, urosepsis), bowel dysfunction, sexual dysfunction, orthostatic hypotension |
| Respiratory | Respiratory failure (cervical myelitis), chronic ventilator dependence, aspiration pneumonia |
| Brainstem | Persistent nausea/vomiting (area postrema), dysphagia, central hypoventilation |
| Immobility | DVT/PE, pressure ulcers, osteoporosis, contractures, muscle wasting |
| Psychological | Depression, anxiety, fatigue, cognitive impairment |
| Autoimmune | Co-existing SLE, Sjögren's, myasthenia gravis, thyroid disease |
| Treatment | Infections (opportunistic, HBV reactivation, meningococcal), myelosuppression, hepatotoxicity, teratogenicity (MMF), PML (rare), steroid complications |
| Iatrogenic | Disease worsening from inappropriate MS DMTs |
High Yield Complications Summary
Most immediately life-threatening: Respiratory failure from cervical LETM (C3-5 phrenic nerve destruction) — monitor FVC serially, prepare for intubation.
Most common cause of cumulative disability: Visual impairment (bilateral severe ON with poor recovery) and motor disability (paraplegia from recurrent LETM with stepwise deterioration).
Most important treatment complication: Meningococcal infection with eculizumab (mandatory vaccination) and HBV reactivation with rituximab (mandatory screening).
Most devastating preventable complication: Exacerbation from MS-specific DMTs (beta-IFN, DMF, fingolimod, natalizumab, alemtuzumab) — these are contraindicated in NMOSD [6].
Prognosis without treatment: > 90% relapsing, 25-50% mortality, stepwise deterioration [5]. With modern immunosuppression: relapse rates reduced 70-95%, but residual disability still accumulates.
Active Recall - NMOSD Complications
References
[1] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf – Section on Transverse myelitis, autonomic impairment [2] Senior notes: Maksim Medicine Notes.pdf – Section 11.8 CNS demyelinating diseases, MS vs NMOSD table [4] Lecture slides: Neurology- Two cases of lower limb weakness.pdf – NMO as autoimmune astrocytopathy, clinical presentation, treatment slides [5] Senior notes: Ryan Ho Neurology.pdf – Section 6.1.2 Neuromyelitis Optica Spectrum Disorders [6] GC Lecture slides: GC 225. Neuroimmunological disorders of the central nervous system.pdf – MS DMT contraindication warning [8] Senior notes: Ryan Ho Opthalmology.pdf – Section 4.3.3 Optic Neuritis, optic atrophy, temporal pallor
High Yield Summary
Definition: NMOSD is an autoimmune astrocytopathy caused by AQP4-IgG targeting water channels on astrocyte foot processes → complement-mediated astrocyte destruction → secondary demyelination and axonal degeneration.
Epidemiology: Asian females (M:F 1:9), onset 30s–50s. More common in Asians (cf. MS in Caucasians).
Cardinal features (3):
- Optic neuritis — bilateral, severe, poor recovery
- LETM — ≥3 spinal segments, symmetrical paraparesis, sensory level, autonomic failure
- Area postrema syndrome — intractable hiccups, nausea/vomiting (unique to NMOSD)
Key lab findings: AQP4-IgG positive (60-80%), CSF pleocytosis WITHOUT oligoclonal bands
Critical management point: MS-specific DMTs (IFNβ, fingolimod, natalizumab, DMF, alemtuzumab) are CONTRAINDICATED — they worsen NMOSD. Use immunosuppressants: azathioprine, MMF, rituximab.
Prognosis: > 90% relapsing course, stepwise deterioration, 25-50% mortality, significant residual deficits per attack.
Key differences from MS: bilateral ON (not unilateral), LETM (not short segment), no oligoclonal bands (not present 90%), no INO, Asian > Caucasian, astrocytopathy (not primary demyelination).
Hypokalemic Periodic Paralysis
Hypokalemic periodic paralysis is a channelopathy characterized by episodic attacks of flaccid muscle weakness associated with transient decreases in serum potassium levels, often triggered by carbohydrate-rich meals, rest after exercise, or stress.
Multiple Sclerosis
Multiple sclerosis is a chronic autoimmune demyelinating disease of the central nervous system characterized by spatially and temporally disseminated inflammatory plaques in the brain and spinal cord, leading to varied neurological deficits.